TRAVERE THERAPEUTICS INC TVTX 深 滬
已收盤 07-18 16:00:00 美东时间
16.11
-0.400
-2.42%
華盛通- 最 高16.74
- 今 開16.65
- 成交量 144.38万股
- 最 低 16.10
- 昨 收 16.51
- 總市值 14.31亿
- 52周最高 25.29
- 市盈率 靜 --
- 換手率 1.63%
- 52周最低 7.931
- 委 比 -33.88%
- 總股本 8880.48万
- 歷史最高 37.04
- 量 比 1.24
- 振 幅 3.88%
- 歷史最低 0.90
- 每 手 1
- 風險率 2.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews
During the last three months, 8 analysts shared their evaluations of Travere Th...
07-02 05:01
单日暴涨130%+，肾病领域再成行业焦点
转自：新康界 4月30日，诺华公司宣布以17亿美元收购美股上市医药公司Regulus(NASDAQ:RGLS)，受此消息影响，Regulus的股价...
06-23 19:50
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Travere To Present New Kidney Drug Data At Global Conference, Shows FILSPARI May Slow Disease Progression
Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in
06-11 19:05
Travere Therapeutics Reports SPARTACUS And PROTECT OLE Data Showing FILSPARI's Proteinuria Reduction And IgA Protection
Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2iNew mechanistic data to show FILSPARI protects against
06-04 04:33
美股周涨跌榜 | 获24亿美元收购！富乐客周内暴涨98%；超微电脑周内涨超44%
富乐客周内暴涨98%，获迪克体育用品拟24亿美元收购；超微电脑周内涨超44%，拿下200亿美元合作协议；联合健康周内跌超23.3%，因涉嫌医疗保险欺诈而遭调查>>
05-17 10:56
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $30 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $30 price target.
05-16 22:11
Travere Therapeutics Receives FDA Acceptance Of Supplemental New Drug Application For FILSPARI In FSGS
PDUFA target action date of January 13, 2026If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure
05-16 04:09
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025
Earnings Call Insights: Travere Therapeutics (TVTX) Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropath...
05-02 11:08
